Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 7/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6440680 | 0.88 | ADORA1 (0.62) | ADORA1ADORA2AKDM4ESQORKDM1A | |
| SCHEMBL6441798 | 0.84 | ADORA2A (0.70) | ADORA1ADORA2ASQORADORA2BDCUN1D1 | |
| SCHEMBL6440842 | 0.83 | ADORA1 (0.65) | ADORA1ADORA2AKDM4EKDM1AADORA2B | |
| SCHEMBL6442616 | 0.80 | ADORA1 (0.74) | ADORA1ADORA2AKDM4ECYP1A2CYP2C19 | |
| SCHEMBL6440878 | 0.80 | ADORA2A (0.63) | ADORA1ADORA2AKDM4ELMNAKDM1A | |
| SCHEMBL6443434 | 0.78 | ADORA1 (0.58) | ADORA1ADORA2AKDM4EKDM1AADORA2B | |
| SCHEMBL6440983 | 0.78 | SQOR (0.73) | ADORA1ADORA2ASQORADORA2B | |
| SCHEMBL6441108 | 0.78 | ADORA1 (0.61) | ADORA1ADORA2AKDM4EKDM1AADORA2B | |
| SCHEMBL6443011 | 0.78 | ADORA1 (0.67) | ADORA1ADORA2AKDM4ELMNACYP1A2 | |
| SCHEMBL6448531 | 0.76 | ADORA1 (0.65) | ADORA1ADORA2AKDM4EKDM1AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1261327-B1 | ADENOSINE RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2005-04-27 | — | — | EP | disclosed |
| US-6586441-B2 | 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders | HOFFMAN-LA ROCHE INC. | 2003-07-01 | — | — | US | disclosed |
| EP-1261327-A2 | ADENOSINE RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2002-12-04 | — | — | EP | disclosed |
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-04 | — | — | US | disclosed |
| WO-2001062233-A2 | ADENOSINE RECEPTOR MODULATORS | F. HOFFMANN LA ROCHE AG (CH) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | ADORA2A, ADORA2B, ADORA1 | ADORA1 3/4885ADORA2A 1/4885KDM4E 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.